{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.92","value":"3726.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Day 1, Cycle 1,n=8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"268.64","value":"11352.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Day 1, Cycle 2,n=4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.75","value":"11121.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Day 1, Cycle 4,n=3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG000","title":"Part 1: GSK2857916 2.50 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Part 1 Population.Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).","reportingStatus":"POSTED","timeFrame":"Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)","title":"Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}